Left Ventricular Diastolic Dysfunction in Patients with Interstitial Lung Disease—A Potential Treatable Trait
Advances in Respiratory Medicine · 04.08.2026 · 94 (4) · 57
DOI: 10.3390/arm94040057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 04.08.2026. Verfasst von Ophir Freund und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pulmonary Medicine, Sourasky Medical Center, Tel Aviv 6423906, Israel. Hauptthemen laut MEDLINE: Ventricular Dysfunction, Left, Lung Diseases, Interstitial. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular comorbidities complicate interstitial lung disease (ILD) and represent potential therapeutic targets, yet the prevalence and clinical impact of left ventricular diastolic dysfunction (LVDD) remain poorly characterized. We aimed to evaluate LVDD as a potential treatable trait within a prospective cohort. Using data from an ILD registry (January 2021–October 2024), we defined clinically relevant LVDD as echocardiographic grade 2 or 3 diastolic dysfunction. Out of 276 patients (median age 69, 44% female), 14% had LVDD, which was almost entirely in patients with fibrosis (97%, p = 0.045) and associated with lower diffusing capacity for carbon monoxide. Survival and clinical analyses restricted to the fibrotic ILD subgroup (n = 241) showed that LVDD was independently associated with a higher hazard for a combined adverse outcome of acute exacerbation, lung transplantation, or death (adjusted HR 1.82, 95% CI 1.03–3.38, p = 0.043), which persisted after 1:2 propensity score matching (HR 2.04). LVDD also independently predicted increased all-cause mortality (adjusted HR 2.10) and reduced 6-min walk distance (median 413 vs. 465 m, β = −0.14, p = 0.036). In conclusion, LVDD is prevalent in fibrotic ILD and carries significant prognostic implications. Given its objective measurability and actionable treatment pathways, LVDD represents a potentially important treatable trait requiring multi-disciplinary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pulmonary Medicine, Sourasky Medical Center, Tel Aviv 6423906, Israel.
- Center of Excellence for Interstitial Lung Diseases, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
- Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Cardiology Department, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
ORCID-Profile: Ophir Freund, Tzlil Hershko, Shir Frydman, Eyal Kleinhendler, Avraham Unterman
Zitieren
APA
Freund, O., Katsoff, U., Hershko, T., Ron, A., Frydman, S., Cohn-Schwartz, D., Kupershmidt, A., Mano, N., Melloul, A., Kleinhendler, E., Bar-Shai, A., & Unterman, A. (2026). Left Ventricular Diastolic Dysfunction in Patients with Interstitial Lung Disease—A Potential Treatable Trait. Advances in Respiratory Medicine, 94(4), 57. https://doi.org/10.3390/arm94040057
Vancouver
Freund O, Katsoff U, Hershko T, Ron A, Frydman S, Cohn-Schwartz D, et al. Left Ventricular Diastolic Dysfunction in Patients with Interstitial Lung Disease—A Potential Treatable Trait. Advances in Respiratory Medicine. 2026;94(4):57. doi:10.3390/arm94040057
BibTeX
@article{Freund2026,
author = {Freund, Ophir and Katsoff, Uriel and Hershko, Tzlil and Ron, Ayala and Frydman, Shir and Cohn-Schwartz, Doron and Kupershmidt, Aviv and Mano, Neta and Melloul, Ariel and Kleinhendler, Eyal and Bar-Shai, Amir and Unterman, Avraham},
title = {Left Ventricular Diastolic Dysfunction in Patients with Interstitial Lung Disease—A Potential Treatable Trait},
journal = {Advances in Respiratory Medicine},
year = {2026},
volume = {94},
number = {4},
pages = {57},
doi = {10.3390/arm94040057}
}
EUVIMED